CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma Journal Article


Authors: Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. S.; Korde, N.; Maclachlan, K. H.; Landau, H. J.; Scordo, M.; Shah, G. L.; Lahoud, O. B.; Giralt, S.; Murata, K.; Hosszu, K. K.; Chung, D. J.; Lesokhin, A. M.; Usmani, S. Z.
Article Title: CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Abstract: Teclistamab, a B-cell maturation antigen (BCMA)- and CD3 -targeting bispeci fic antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but ef ficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune pro filing identi fied that effector CD8 + T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management.
Keywords: memory; antibody; target; subsets; maturation antigen
Journal Title: Blood Advances
Volume: 8
Issue: 7
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2024-04-09
Start Page: 1600
End Page: 1611
Language: English
ACCESSION: WOS:001215169100001
DOI: 10.1182/bloodadvances.2023011225
PROVIDER: wos
PMCID: PMC10987849
PUBMED: 37878808
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK authors are Ross S. Firestone and SaadZ. Usmani -- Urvi A. Shah's middle initial is incorrectly listed in the publication Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sergio Andres Giralt
    1053 Giralt
  2. Kazunori Murata
    33 Murata
  3. Hani Hassoun
    329 Hassoun
  4. Heather Jolie Landau
    419 Landau
  5. Weige Qin
    10 Qin
  6. Alexander Meyer Lesokhin
    363 Lesokhin
  7. David Chung
    240 Chung
  8. Michael Scordo
    367 Scordo
  9. Neha Sanat Korde
    226 Korde
  10. Gunjan Lalitchandra Shah
    419 Shah
  11. Oscar Boutros Lahoud
    133 Lahoud
  12. Urvi A Shah
    187 Shah
  13. Menglei Zhu
    36 Zhu
  14. Kinga Hosszu
    39 Hosszu
  15. Dhwani Patel
    41 Patel
  16. Carlyn Rose Tan
    130 Tan
  17. Devin Pyne Mcavoy
    30 Mcavoy
  18. Saad Zafar Usmani
    297 Usmani
  19. Issam S. Hamadeh
    22 Hamadeh
  20. Alice Wang
    11 Wang